Arbutus Biopharma Corp ABUS
📋 Company Profile
| Industry | Biotechnology |
| Country | CA |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2010-11-13 |
| Shares Out. | 197,540,000 |
| Website | arbutusbio.com/ ↗ |
| Phone | 16044193200 |
| Employees | 19 |
| Revenue | $179.1M |
| Gross Profit | $179.1M |
| Net Income | $169.7M |
| Total Assets | $277.2M |
| Total Liabilities | $17.0M |
| Equity | $260.2M |
About Arbutus Biopharma Corp
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Arbutus Biopharma Corp is a publicly traded company under the ticker symbol ABUS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)